All In Biotech

Drug Trial Radar · NCT06780462

Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

134

Planned (sponsor's estimate)

Start

Jun 24, 2025

Primary completion

Dec 24, 2027

Study completion Jun 24, 2028

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In patients with Behçet's syndrome (BS), deep venous thrombosis (DVT) is thought to result from inflammation of the vessel wall rather than hyper coagulability. Post Thrombotic Syndrome (PTS) is frequent especially with recurrent episodes of deep vein thrombosis and may result in leg ulcers that are very difficult to treat. Vascular involvement is a major cause of morbidity and mortality among BS patients. However, one of the most controversial issues regarding the management of BS is whether DVT should be treated with anticoagulants. Moreover, use of anticoagulants exposes patients to serious bleeding, especially in those who presents simultaneous arterial aneurysms. However, many physicians are still using anticoagulants. This is the first prospective, randomized study assessing benefits of corticosteroids associated with anticoagulant compared to that of corticosteroids alone in DVT in BS patients. It will validate or not the use of anticoagulants in those situations. It will allow a direct comparison of the safety profile of those two schemes of treatment.

Conditions

  • Behcet Syndrome

Interventions

  • Corticosteroids + RivaroxabanDrug

    Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market) and Rivaroxaban

  • Corticosteroids aloneDrug

    Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of successTime frame: At 6 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • CHU BORDEAUX Hôpital Saint-André

    Bordeaux, France · Recruiting

  • Ambroise Paré hospital AP-HP

    Boulogne-Billancourt, France · Recruiting

  • CHU Caen

    Caen, France · Recruiting

  • Hopital Henri Mondor AP-HP

    Créteil, France · Recruiting

  • Chu de Grenoble

    Grenoble, France · Recruiting

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France · Recruiting

  • Hcl, Hopital de La Croix Rousse

    Lyon, France · Recruiting

  • Centre Hospitalier de Melun

    Melun, France · Recruiting

  • CHRU DE Nancy Hôpitaux de Brabois

    Nancy, France · Recruiting

  • Hôpital Hôtel-Dieu

    Nantes, France · Recruiting

  • Hopital Européen Georges Pompidou AP-HP

    Paris, France · Recruiting

  • Hôpital Lariboisière AP-HP

    Paris, France · Recruiting

  • Hôpital Saint Antoine AP-HP

    Paris, France · Recruiting

  • Hôpital Tenon AP-HP

    Paris, France · Recruiting

  • La Pitié Salpetriere hospital

    Paris, France · Recruiting

  • CHU Bordeaux- GHU SUD hôpital Haut-Lévêque

    Pessac, France · Recruiting

  • CHU DE ROUEN, Hôpital CHARLES NICOLLE

    Rouen, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.